Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area

被引:83
作者
Martinez, E.
Milinkovic, A.
Buira, E.
de Lazzari, E.
Leon, A.
Larrousse, M.
Lonca, M.
Laguno, M.
Blanco, J. L.
Mallolas, J.
Garcia, F.
Miro, J. M.
Gatell, J. M.
机构
[1] Hosp Clin Univ, Inst Invest Biomed August Pi & Sunyer, Infect Dis Unit, Barcelona, Spain
[2] Generalitat Catalunya, Dept Sanitat & Seguretat Social, Programa Prevenc Assistencia Sida, Barcelona, Spain
关键词
antiretroviral therapy; causes; death; HIV-infected persons; incidence;
D O I
10.1111/j.1468-1293.2007.00468.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Since the introduction of highly active antiretroviral therapy (HAART), the incidence of death in HIV-infected patients has dramatically decreased, and causes of death other than those related to HIV infection have increased, although it is unclear how these parameters compare with those in the age-matched general population living in the same geographical region. Methods Consecutive HIV-infected adults who were prescribed HAART in our hospital were prospectively followed from January 1997 to December 2004 or until death, loss to follow-up or discontinuation of HAART. Estimations of the annual incidence and causes of death in the general population of similar age in Catalonia per calendar year in the study period were obtained and compared with those in the HIV-infected cohort. Results There were 235 deaths among the 4471 patients on HAART (5%). The incidence of mortality decreased over time in HIV-infected patients (P < 0.001; chi(2) test for trend), although it has remained approximately five times higher than that for the age-matched general population. AIDS-related events were the most common cause of death (n=95; 40%), although they significantly decreased over time (P < 0.001; chi(2) test for trend), whereas liver diseases (P < 0.001; chi(2) test for trend) and non-AIDS-defining infections (P=0.008; chi(2) test for trend) significantly increased over time. Infections in general (33 times higher), liver diseases (11 times higher) and non-Hodgkin lymphoma (5 times higher) were overrepresented as causes of death in the HIV-infected cohort compared with the age-matched general population. Conclusions Non-AIDS-defining infectious diseases, liver diseases, and non-Hodgkin lymphoma represent specific targets for efforts to further decrease mortality in HIV-infected patients receiving HAART.
引用
收藏
页码:251 / 258
页数:8
相关论文
共 32 条
[1]  
[Anonymous], 13 C RETR OPP INF DE
[2]  
[Anonymous], 11 C RETR OPP INF SA
[3]   Comparisons of causes of death and mortality rates among HIV-infected persons - Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras [J].
Crum, NF ;
Riffenburgh, RH ;
Wegner, S ;
Agan, BK ;
Tasker, SA ;
Spooner, KM ;
Armstrong, AW ;
Fraser, S ;
Wallace, MR .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (02) :194-200
[4]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[5]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[6]  
GARARD L, 2002, J ACQ IMMUN DEF SYND, V30, P479
[7]   Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count [J].
García, F ;
de Lazzari, E ;
Plana, M ;
Castro, P ;
Mestre, G ;
Nomdedeu, M ;
Fumero, E ;
Martínez, E ;
Mallolas, J ;
Blanco, JL ;
Miró, JM ;
Pumarola, T ;
Gallart, T ;
Gatell, JM .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (02) :702-713
[8]  
*I EST CAT, 2007, EST POBL
[9]   Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population [J].
Jaggy, C ;
von Overbeck, J ;
Ledergerber, B ;
Schwarz, C ;
Egger, M ;
Rickenbach, M ;
Furrer, HJ ;
Telenti, A ;
Battegay, M ;
Flepp, M ;
Vernazza, P ;
Bernasconi, E ;
Hirschel, B .
LANCET, 2003, 362 (9387) :877-878
[10]   All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population [J].
Keiser, O ;
Taffé, P ;
Zwahlen, M ;
Battegay, M ;
Bernasconi, E ;
Weber, R ;
Rickenbach, M .
AIDS, 2004, 18 (13) :1835-1843